{"title":"阿米万他单抗与奥希替尼联合治疗表皮生长因子受体突变的非小细胞肺癌的中枢神经系统抗肿瘤活性:一份病例报告","authors":"Ebaa Al-obeidi, Jonathan Riess, David Gandara","doi":"10.53876/001c.90815","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CNS antitumor activity of amivantamab added to osimertinib in EGFR-mutant non–small cell lung cancer with MET amplification as acquired resistance to osimertinib: a case report\",\"authors\":\"Ebaa Al-obeidi, Jonathan Riess, David Gandara\",\"doi\":\"10.53876/001c.90815\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":237891,\"journal\":{\"name\":\"International Journal of Cancer Care and Delivery\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer Care and Delivery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53876/001c.90815\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Care and Delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53876/001c.90815","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CNS antitumor activity of amivantamab added to osimertinib in EGFR-mutant non–small cell lung cancer with MET amplification as acquired resistance to osimertinib: a case report